Congressional Investigation into Alzheimer’s Drug Aduhelm Faults the F.D.A. and Biogen

https://ift.tt/ylFW84Z

The report said the F.D.A.’s approval process for Aduhelm was “rife with irregularities” and criticized Biogen for setting an “unjustifiably high price.”

Source link

source https://financetin.com/congressional-investigation-into-alzheimers-drug-aduhelm-faults-the-f-d-a-and-biogen/financetin.com